Skye Bioscience, Inc. (SKYE) › Cash & EquivalentsSkye Bioscience, Inc. (SKYE) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2011: $13.9K2012: $26.4K2013: $52.2K2014: $207.3K2015: $3.22M2016: $64.8K2017: $260.0K2018: $1.85M2023: $1.26M2024: $68.42M2025: $5.88M$5.88M2011Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$5.88M-91.4%2024$68.42M+5345.1%2023$1.26M—2018$1.85M+613.0%2017$260.0K+301.0%2016$64.8K-98.0%2015$3.22M+1453.7%2014$207.3K+297.3%2013$52.2K+97.6%2012$26.4K+89.8%2011$13.9K—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share